Endoca Joins Tough Mudder as Its Official CBD Partner

Endoca’s 100% Organic CBD Brings Post-Workout Recovery to Tough Mudder Participants

SPOKANE, Wash.June 6, 2019 /PRNewswire/ — Endoca, the leader of organic cannabis products, today announces its strategic move to join forces with Tough Mudder as its official CBD partner and sponsor. With participants from around the world, this obstacle-course focused event harnesses everyone from weekend warriors at their 5Ks to athletes at the top of their game as part of the competitive events. At Tough Mudder’s 2019 North America and United Kingdom events, Endoca will provide CBD education and product samples to participants.

Tough Mudder logo

To help Mudders recover quicker after they cross the finish line, Endoca is offering sample drops of its organic CBD oil. Participants will also have the opportunity to learn from Endoca’s team of experts about the new CBD phenomena and how it interacts with the body’s endocannabinoid system to treat various physical and neuro-related ailments. As of December 2018, CBD was made legal at the US federal level through the Farm Bill.

Endoca is sponsoring Tough Mudder’s iconic Pyramid Scheme obstacle which has participants in teams working together to get over a 12 foot slanted wall. At each event, there will be an Endoca CBD Starter Pack raffled off as well as a one-year supply of CBD products.  Anyone who wants to enter should pay close attention to the event M.C.’s announcements for details.

“Through this Tough Mudder partnership, Endoca is helping athletes at the peak of fitness maintain their overall wellness. When you think of athletes at the top of their game, it seems as though there’s nothing that can slow them down,” says Henry Vincenty, CEO of Endoca. “We’ve found that particularly strenuous workouts can slow down the recovery process – this is where CBD comes in. By using CBD in various forms before, during and after a workout, we’ve found the body to have a quicker return to top condition.”

“We are thrilled to be partnering with Endoca to provide Mudder Nation with the right recovery products to help them power through training and event day,” says Kyle McLaughlin President of Tough Mudder.  “Endoca’s CBD oil is the purest we’ve found on the market and we think our participants will really be impressed.”

About Endoca:
Endoca is leading the revolution in plant-based medicine, unlocking the secrets of nature, and setting the gold standard in the cannabis industry for natural pharmaceutical-grade hemp-made products. With 100% organic hemp in all of its CBD products, Endoca is taking wellness to the next level. Its primary goal is to develop high-quality hemp supplements with a broad range of cannabinoids and other natural molecules found in hemp to identify their distinct properties. For more information on Endoca, visit www.endoca.com.

About Tough Mudder:
Founded in 2010 with the launch of the Tough Mudder obstacle course event series, Tough Mudder Inc. has become a leading global sports and active lifestyle brand. With more than 3 million participants, the company hosts more than 130 non-competitive (Mini Mudder, Tough Mudder 5K and Tough Mudder Classic) and competitive (Tougher Mudder, Toughest Mudder and World’s Toughest Mudder) events annually in 10 countries including the United StatesCanadaUnited Kingdom and Germany. The company’s content arm provides the more than millions of engaged online brand enthusiasts with fitness, nutrition and wellness content delivered daily across social and digital platforms. Other NAM sponsorship partners include 3M’s Nexcare™ and ACE™ brands, CELSIUS, Soap & Glory, EveryManJack, Navy Federal Credit Union, Alanic, Chipotle, MuscleTech and Viewsport. UK and Germany partners include Lucozade Sport, Brewdog, Snickers Protein, Toyo Tyres, Black Tower Wine, Rawbite, and Strandgut. For more information, visit www.toughmudder.com.

Please follow and like us:

CBD maker Charlotte’s Web to begin trading on Toronto Stock Exchange

Image result for Charlotte’s Web cbd


Charlotte’s Web, a Boulder, Colorado-based CBD manufacturer, said Wednesday it received approval to uplist to the Toronto Stock Exchange (TSX).

The company expects to start trading on the TSX on May 31 and will maintain its Canadian Securities Exchange ticker CWEB.

The move to the TSX – the world’s ninth-largest exchange in terms of market capitalization – will grant Charlotte’s Web exposure to a wider capital-markets audience and likely attract increased numbers of institutional investors, the company said.

The company on Tuesday reported quarterly revenues of $21.7 million for the three months ended Mar. 31, 2019, and net income of $2.3 million.

More details on the company’s move to the TSX can be found here.

Please follow and like us:

Cannabis stocks fall after FDA hearing on CBD finds conflicting views of substance

Cannabis stocks were mostly lower Monday, as investors digested the first reports from Friday’s regulatory hearing on cannabis and its ingredients and the news that Illinois is legalizing weed for adult recreational use.

The U.S. Food and Drug Administration conducted its first-ever hearing on cannabis and its nonintoxicating ingredient CBD all day Friday with more than 100 speakers offering views, including researchers, health professionals, advocates, manufacturers and opponents.

The hearing came after hemp was legalized in the 2018 Farm Bill, leading to a crop of hemp-based products being sold online and in stores, including at mom-and-pop stores. But CBD, which is widely held to have wellness properties, particularly in treating pain, inflammation and anxiety, was not included in the lifting of the federal ban and was instead placed under the regulatory purview of the FDA. That’s because it’s the key ingredient in the only cannabis-based drug to win FDA approval, GW Pharmaceuctical’s PLC’s GWPH, +0.84%  Epidiolex, a treatment for severe forms of childhood epilepsy.

The FDA has warned companies that because it views CBD as a drug, it cannot be added to food or beverages or marketed as a dietary supplement in interstate commerce. But it has also said that given the strong public interest in CBD as a wellness aid, it will seek to help provide pathways to regulatory approval.

The hearing “highlighted the messy state of the industry, with widespread use of CBD products with minimal standardization, evidence for benefit and understanding of safety profile,” said Evercore ISI analysts led by Josh Schimmer in a note to clients.

The discussion was “at times quite absurd with outlandish claims, inconsistent messages and an undercurrent of potential safety concerns,” said the analyst. It was however quite favorable for GW Pharma, as the FDA made clear that it wants to ensure the substance continues to be subjected to clinical research, he wrote. GW Pharma shares offered a rare glimpse of green in the cannabis sector Monday, gaining 1.1%

“Considering the extent to which the CBD cat is out of the bag, it remains to be seen how the FDA will regulate this industry; it might not have adequate resources to fully monitor and police it,” said Schimmer.

At CIBC, analysts noted that a World Health Organization report found CBD to be safe and nonaddictive, although they acknowledged that most experts fret there is still insufficient data from trials. What is clear is the strong demand for CBD, they wrote in a note to clients, citing a speaker at the hearing from Consumer Reports, who said that about 65 million Americans have tried CBD and 63% found it effective.

“Furthermore, more Americans’ primary concern was pricing rather than safety,” said the note.

Many of Friday’s speakers underscored the need for quality testing and safety standards, as much of the CBD currently available is substandard or mislabeled with incorrect amounts of CBD or even THC, the intoxicating ingredient in cannabis, as well as impurities including pesticides and bacteria. CIBC is expecting more clarity from the FDA in the coming year.

Please follow and like us:

Researchers have discovered CB3 Cannabinoid Receptor

Researchers have discovered a new cannabinoid receptor, CB3, one that could open a new door of healing possibilities.

This isn’t anything like anyone has seen before: This new research suggests that cannabis may influence the human body in new and extraordinary ways.

Before we go into more detail, let’s go over some brief history:

After the U.S. government belatedly allowed scientists to move forward in research of the possible medical uses of cannabis, whole dimensions of human biochemistry which formerly existed in the shadows suddenly shifted into the light. In the 1990s, the discovery of the endocannabinoid system came about—a vitally essential component of the central nervous system that plays a role in everything; from cognitive processes and pain sensation to appetite regulation and physical activity.

It was the discovery of the decade. In a phenomenally narrow window, science has gained a deeper comprehension of how the mammalian body manages and regulates itself.

Because the endocannabinoid system grasps various domains of the human experience, it is a gargantuanly productive ground for research.

The biggest focus in the endocannabinoid system is two cannabinoid receptors most commonly referred to as CB1 and CB2. These molecules are where the magic happens. Like all biochemical receptors, CB1 and CB2 are protein molecules that receive chemical signals from outside the cell. Think of them like the area on your television that you point the remote control at. They sit dormant until they receive a signal, then they spring into action.

What is the CB3 Cannabinoid Receptor?
For years, CB1 and CB2 stood by themselves. But now, scientists think they’ve pinpointed a new cannabinoid receptor, one that could change everything we know about the endocannabinoid system.

The molecule in question goes by the name GPR55 but may soon be known as CB3. The molecule itself was first discovered in 1999 in various parts of the brain—the hippocampus, cerebellum, thalamus, etc. But newer research has discovered that it also hides out in more remote parts of the body, such as the spleen, GI tract and adrenal glands.

If this molecule is truly a cannabinoid receptor, that means the current understanding of the endocannabinoid system is immensely fragmentary. This molecule is distinctly different from CB1 and CB2, which share a lot of similar characteristics. In comparison, GPR55 shares less than 15% of its amino acid identity with either.

The potential here is extremely huge. It could explain why CBD oil has such a diverse range of health benefits, a variety of which are proven through trials but poorly understood from a scientific perspective. If researchers could unlock the mechanism by which medical cannabis operates, it could lead us toward developing new and more effective therapies for all kinds of diseases. Woo!!

But it’s not just that. The new receptor is also found in cancer cells.

The presence of GPR55 in cancer cells might sound scary, but it’s worth getting excited about.

While the exact functions and pharmacology of GPR55 are far from understood, if research discovers what it’s doing in cancer cells, we’ll know more about cancer itself: How it emerges, how it spreads and how to stop it.

And if turns out that we can influence cancer by manipulating a cannabinoid receptor or the body’s endocannabinoid system, we’ll have more weapons in our arsenal of anti-tumor remedies. That’s huge!!!

One of the noteworthy theories circulating about the properties of CB3 is that the body may have the ability to transform one kind of cannabinoid to another. If that’s true, and cancer cells use CB3 for some corrupt purpose, it could be possible to engineer a change-resistant form of cannabinoid that slows the progression of tumors.

Of course, that’s entirely theoretical—and a long way off. However, the possibilities are worth the hype! CB3 could present the next breakthrough in treating human suffering. It’s another level up in hope of reversing diseases previously believed uncurable.

Please follow and like us: